Cardiff Oncology, Inc. (CRDF) News & Overview - Discounting Cash Flows
CRDF
Cardiff Oncology, Inc.
CRDF (NASDAQ)

CRDF's Business Model

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.cardiffoncology.com
CEO (Chief Executive Officer) Mark Erlander
Number of Employees
IPO date July 27, 2004

CRDF Latest News

Contact
CountryUS
Address11055 Flintkote Avenue
CitySan Diego
StateCA
Phone858 952 7570
Zip Code92121
Other Identifiers
CIK0001213037
ISINUS14147L1089
CUSIP14147L108
Open4.09
Previous Close4.08
Volume772.3 Thou.
Average Volume1.17 Mil.
Day’s Range4.025 – 4.2
52 Week Range2.01-5.64
MA (50)3.2478
MA (200)3.35885
Market Cap276.7 Mil.
Shares Out.66.53 Mil.
Earnings DateAug 06, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for CRDF

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us